How many drugs treat Pityriasis versicolor?

Drug Landscape tracks 8 marketed treatments for Pityriasis versicolor (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pityriasis-versicolor.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pityriasis versicolor — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pityriasis versicolor (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pityriasis versicolor, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Mentax	BUTENAFINE	Bayer	Benzylamine Antifungal	Cytochrome P450 2D6	1996-01-01
Exelderm	SULCONAZOLE	Journey	Azole Antifungal	Cytochrome P450 2C19	1985-01-01
Loprox	CICLOPIROX	Bausch Health	ciclopirox	Poly [ADP-ribose] polymerase 1	1982-01-01
Nizoral	ketoconazole	Johnson & Johnson (Janssen)	Azole Antifungal [EPC]	Aldehyde oxidase, Cytochrome P450 21, Sodium/nucleoside cotransporter 1	1981-06-26
Lotrimin	clotrimazole	Bayer AG	Azole Antifungal [EPC]	7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6	1975-01-01
Monistat	miconazole	Johnson & Johnson (Janssen)	Imidazole antifungal	7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6	1974-01-01
Selsun	SELENIUM SULFIDE	Chattem	selenium sulfide		1951-01-01
Penlac	Penlac	9305-9954 Quebec Inc		Deoxyhypusine hydroxylase, Poly [ADP-ribose] polymerase 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in Pityriasis versicolor
Johnson & Johnson (Janssen) · 2 drugs in Pityriasis versicolor
Bausch Health · 1 drug in Pityriasis versicolor
Bayer · 1 drug in Pityriasis versicolor
Bayer AG · 1 drug in Pityriasis versicolor
Chattem · 1 drug in Pityriasis versicolor
Journey · 1 drug in Pityriasis versicolor
9305-9954 Quebec Inc · 1 drug in Pityriasis versicolor

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pityriasis versicolor:

Cite this brief

Drug Landscape (2026). Pityriasis versicolor — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pityriasis-versicolor. Accessed 2026-06-10.

Pityriasis versicolor full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing